Note 17 - Segment Reporting

9 Months Ended

Sep. 30, 2023

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

NOTE 17. SEGMENT REPORTING

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

Prior to the DERMAdoctor Acquisition in November 2021, the Company was managed as a single segment focused on commercializing Avenova Spray in the United States. After the DERMAdoctor Acquisition, the Company began managing and aggregating its operational and financial information in accordance with two reportable segments: (1) Eyecare & Wound Care and (2) Skincare. The Eyecare & Wound Care segment consists of products historically sold by NovaBay prior to the DERMAdoctor Acquisition. The Skincare segment consists of products acquired in the DERMAdoctor Acquisition and skincare products subsequently sold under the DERMAdoctor brand.

Select financial information for each segment is as follows:

	Three					Three
	Months					Months
	Ended		Percentage			Ended		Percentage
	September		of Total			September		of Total
	30,		Sales,			30,		Sales,
	2023		Net			2022		Net
Eyecare & Wound Care	$	2,481		76	%	$	2,507		66	%
Skincare		784		24	%		1,319		34	%
Total sales, net	$	3,265		100	%	$	3,826		100	%

	Three						Three
	Months						Months
	Ended			Percentage			Ended			Percentage
	September			of Total			September			of Total
	30,			Operating			30,			Operating
	2023			Loss			2022			Loss
Eyecare & Wound Care	$	(698	)		63	%	$	(257	)		56	%
Skincare		(418	)		37	%		(200	)		44	%
Total operating loss	$	(1,116	)		100	%	$	(457	)		100	%

	Nine Months					Nine Months
	Ended		Percentage			Ended		Percentage
	September		of Total			September		of Total
	30,		Sales,			30,		Sales,
	2023		Net			2022		Net
Eyecare & Wound Care	$	8,354		76	%	$	7,646		71	%
Skincare		2,645		24	%		3,115		29	%
Total sales, net	$	10,999		100	%	$	10,761		100	%

	Nine Months						Nine Months
	Ended						Ended
	September			Percentage			September			Percentage
	30,			of Total			30,			of Total
	2023			Operating Loss			2022			Operating Loss
Eyecare & Wound Care	$	(3,094	)		74	%	$	(3,605	)		72	%
Skincare		(1,111	)		26	%		(1,386	)		28	%
Total operating loss	$	(4,205	)		100	%	$	(4,991	)		100	%